JXJianmin Xu

Jianmin Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianmin Xu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Dexiang Zhu

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Guodong He

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Liangliang Yang

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Meiling Ji

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Peng Zheng

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Qingyang Feng

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer

    by Yihao Mao, Qingyang Feng, Peng Zheng, Liangliang Yang, Dexiang Zhu, Wenju Chang, Meiling Ji, Guodong He, Jianmin Xu

    The role of mast cells (MCs) in colorectal cancer (CRC) progression was controversial. Thus, our study was designed to evaluate the prognostic value of MCs as well as their correlation with immune microenvironment. A retrospective cohort of CRC patients of stages I–IV was enrolled in our study. Consecutive patients (854) were divided into training set (427 patients) and validation set (427 patients) randomly. The findings were further validated in a GEO cohort, GSE39582 (556 patients). The mast cell density (MCD) was measured by immunohistochemical staining of tryptase or by CIBERSORT algorithm. Low MCD predicted prolonged overall survival (OS) in training and validation set. Moreover, MCD was identified as an independent prognostic indicator in both sets. Better stratification for CRC prognosis can be achieved by building a MCD based nomogram. The prognostic role of MCD was further validated in GSE39582. In addition, MCD predicted improved survival in stages II and III CRC patients receiving adjuvant chemotherapy (ACT). Multiple immune pathways were enriched in low MCD group while cytokines/chemokines promoting anti‐tumor immunity were highly expressed in such group. Furthermore, MCD was negatively correlated with CD8+ T cells infiltration. In conclusion, MCD was identified as an independent prognostic factor, as well as a potential biomarker for ACT benefit in stages II and III CRC. Better stratification of CRC prognosis could be achieved by building a MCD based nomogram. Moreover, immunoactivation in low MCD tumors may contributed to improved prognosis.